SU 5402

CAT: 0804-HY-10407-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10407-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively.
CAS Number
[215543-92-3]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
FGFR; PDGFR; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/SU-5402.html
Purity
99.86
Solubility
DMSO : ≥ 30 mg/mL
Smiles
O=C(CCC1=C(NC=C1C)/C=C2C(NC3=C\2C=CC=C3)=O)O
Molecular Formula
C17H16N2O3
Molecular Weight
296.32
Precautions
H302, H315, H319, H335
References & Citations
[1]Sun L, et al. Design, synthesis, and evaluations of substituted 3-[ (3- or 4-carboxyethylpyrrol-2-yl) methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem. 1999 Dec 16;42 (25) :5120-30.|[2]Kachel P, et al. Phosphorylation of pyruvate kinase M2 and lactate dehydrogenase A by fibroblast growth factor receptor 1 in benign and malignant thyroid tissue. BMC Cancer. 2015 Mar 18;15:140.|[3]Trzcińska-Daneluti AM, et al. RNA Interference Screen to Identify Kinases That Suppress Rescue of ΔF508-CFTR. Mol Cell Proteomics. 2015 Jun;14 (6) :1569-83.|[4]Izikki M, et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest. 2009 Mar;119 (3) :512-23.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PDGFRβ; VEGFR2/KDR/Flk-1

Popular Products